As you know, lung cancer is the most deadly cancer in the world, killing more than breast, prostate and colon cancers combined. However, according to statistics from the American Cancer Society, lung cancer survival is better with earlier diagnosis. Our mission at VisionGate is to have a positive impact and save lives using our LuCED® lung test to help find lung cancer at an early stage – when treatment options are more effective.
VisionGate’s LuCED lung test is being developed for future availability through our CLIA laboratory to aid physicians in early detection of lung cancer. The LuCED lung test requires a sputum sample that can be collected from spontaneous coughs over a three-day period using a take-home kit that the patient receives from your office.
Patients then ship the LuCED test kits to the VisionGate Biosignature Laboratories (VBL) where samples are processed on our proprietary Cell-CT™ platform. The Cell-CT platform is the world’s first automated 3D cell imaging platform that computes high-resolution biosignatures from intact cells. The LuCED test classifies the cells as normal or abnormal. Our licensed cytologists then screen the images followed by a review by our pathologist and a sign out of the case as normal or abnormal. Those results are sent to the ordering physician within two to four weeks.
VisionGate was founded by Dr. Alan Nelson, a physicist, bioengineer and entrepreneur who previously developed the world’s first automated screening test to detect cervical cancer, marketed today as the FocalPoint system by Becton Dickinson.
The LuCED lung test is not yet available to the public, but please enter your name and email in the form to the right and we’ll notify you as soon as it is! Or, please call 602.354.8862 to request a presentation on out LuCED test.